Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C2ZL
|
|||
| Former ID |
DCL000440
|
|||
| Drug Name |
Ataciguat
|
|||
| Synonyms |
Ataciguat [INN]; HMR 1766; HMR-1766; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19Cl2N3O6S3
|
|||
| Canonical SMILES |
C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl
|
|||
| InChI |
1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)
|
|||
| InChIKey |
PQHLRGARXNPFCF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 254877-67-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Atrial natriuretic peptide receptor A (NPR1) | Target Info | Activator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5141). | |||
| REF 2 | ClinicalTrials.gov (NCT00799656) Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain. U.S. National Institutes of Health. | |||
| REF 3 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.